in the quality of life of immunosuppressed individuals and elderly people. To develop a 23 new oral therapic options for candidiasis, a non-pathogenic commensal oral probiotic 24 microorganism, Streptococcus salivarius K12 was evaluated for its ability to modulate 25 Candida albicans growth in vitro and its therapeutic activity was tested on an 26 experimental oral candidiasis model. 27 In vitro inhibition of mycelial growth of C. albicans was determined by plate assay 28 and fluorescent microscopy. Addition of S. salivarius K12 to modified RPMI1640 
54
The probiotic strain Streptococcus salivarius K12 was originally isolated from the 55 saliva of a healthy child and produces several megaplasmid-encoded bacteriocin-like 56 inhibitory substances (BLIS) such as the lantibiotics salivaricin A and salivaricin B (11, 57 13, 31). It has been used commercially as a probiotic for more than a decade and has 58 numerous studies supporting its safety (3, 4, 5 The procedure of scoring the severity of oral infection was performed as described 184 previously (27). Forty-eight hours after inoculation mice were sacrificed by cervical 185 dislocation and the severity of the lesion of the tongue was evaluated by scoring the 186 'fur' coating on each tongue and the squamous disorder as follows：0, normal; 1, fur in 187 less than 20%; 2, fur in more than 21% but less than 90%; 3, fur in more than 91% and 188 on the squamous layer; 4, thick fur in more than 91% and on the squamous layer (12, 189 27). of Candida (Fig. 4) caused a dose-dependent improvement in symptom score and fungal burden (Fig. 6) . There on the tongues of mice administered S. salivarius K12 there were less lesions 301 observed than compared to the tongues of the control mice ( Fig.7A and B) . Even 302 though there was no total eradication as observed in the control using fluconazole in the 303 mice that were administered S. salivarius K12 at 30 mg/ml (3 x 10 9 CFU/ml), there was illustrated by the histopathology of tongue sections ( Fig. 8A and B human health (7, 16, 19, 21, 24 .75 mg/ml, h; 7.5 mg/ml, i; 15 mg/ml, j; 30 mg/ml (1.2☓10 7 -3☓10 9 CFU/ml). (control n=15; S. salivarius K12 7.5mg/ml n=7; 15mg/ml n=12; 30mg/ml n=15;
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Fluconazole 2mg/ml n=6) were inoculated with C. albicans TIMM1768, and S. mouse, B; representative mouse given S. salivarius K12 (30mg/ml; 3☓10 9 CFU/ml).
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Sections were stained with Periodic Acid-Schiff. 
